Kimberly Davis, MS

Director, Surveys and Observational Studies

MS, Pharmaceutical Policy and Evaluative Sciences
BS, Pharmacy
University of North Carolina, Chapel Hill, NC

Kim Davis, MS, is a Director of Surveys and Observational Studies at RTI-HS. She worked in the pharmaceutical industry for 4 years as a Global Health Outcomes manager before joining RTI-HS in 2003. In her current role, she combines clinical experience as a pharmacist, industry experience, and study of pharmaceutical policy with practical research. She has worked with various multidisciplinary teams in the pharmaceutical industry, including commercial, clinical, global pricing, epidemiology, biomedical data sciences, international product development, and clinical trial project teams. She has excellent interpersonal skills and is highly motivated, organized, and efficient, with strong oral and written communication skills that allow her to build and maintain rapport with team members, key opinion leaders, and experts.

Ms. Davis has extensive experience leading and serving as a project manager for multiple types of projects, including large scale prospective observational studies, epidemiologic studies, patient outcomes research, and risk management programs in the United States and Europe. Ms. Davis’ project experience includes study design and implementation, patient and site recruitment, and investigator training. In addition, she has assisted with the development of protocols and physician and patient surveys for risk evaluation and mitigation strategy (REMS) plans to support new drugs in development  as required by the Food and Drug Administration (FDA) and to support  risk minimisation studies as required by the European Medicines Agency. She also specializes in the development and evaluation of questionnaires designed to measure health-related quality of life, patient satisfaction, resource utilization, and other patient-reported outcomes. As part of the questionnaire-development process, Ms. Davis has assisted with the moderation of focus groups and cognitive interviews with a variety of patient populations and with physicians. Ms. Davis has also served as a consultant for various health outcomes projects (e.g., large data collection, literature reviews, clinical trials) across a number of therapeutic areas, including arthritis, attention-deficit/hyperactivity disorder, allergic rhinitis, asthma, bipolar disorder, blood disorders, cancer, dementia, depression, diabetes, gastrointestinal disorders, insomnia, migraine, obesity, ophthalmic disorders, hereditary angioedema, respiratory disorders, and women’s health portfolios. She has also developed economic models and value proposition dossiers to assist international operating companies with reimbursement submissions to assure optimal reimbursement of products at launch.